Skip to Content

We invite you to try out our new beta eCFR site at https://ecfr.federalregister.gov. We’ve made big changes to make the eCFR easier to use. Be sure to leave feedback using the 'Feedback' button on the bottom right of each page!

Notice

Advisory Committees; Tentative Schedule of Meetings for 2013

A Notice by the Food and Drug Administration on 01/02/2013

Document Details

Information about this document as published in the Federal Register.

Printed version:
PDF
Publication Date:
01/02/2013
Agencies:
Food and Drug Administration
Document Type:
Notice
Document Citation:
78 FR 104
Page:
104-105 (2 pages)
Agency/Docket Number:
Docket No. FDA-2012-N-0001
Document Number:
2012-31475
Document Details
Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Page views:
632
as of 03/08/2021 at 8:15 pm EST
Document Statistics
Enhanced Content

Relevant information about this document from Regulations.gov provides additional context. This information is not part of the official Federal Register document.

Docket Number:
FDA-2012-N-0001
Enhanced Content
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA) is announcing a tentative schedule of forthcoming meetings of its public advisory committees for 2013. During 1991, at the request of the Commissioner of Food and Drugs (the Commissioner), the Institute of Medicine (the IOM) conducted a study of the use of FDA's advisory committees. In its final report, one of the IOM's recommendations was for the Agency to publish an annual tentative schedule of its meetings in the Federal Register. This publication implements the IOM's recommendation.

Start Further Info

FOR FURTHER INFORMATION CONTACT:

Teresa L. Hays, Advisory Committee Oversight and Management Staff (HF-4), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 32, rm. 5290, Silver Spring, MD 20993, 301-796-8220.

End Further Info End Preamble Start Supplemental Information

SUPPLEMENTARY INFORMATION:

The IOM, at the request of the Commissioner, undertook a study of the use of FDA's advisory committees. In its final report in 1992, one of the IOM's recommendations was for FDA to adopt a policy of publishing an advance yearly schedule of its upcoming public advisory committee meetings in the Federal Register; FDA has implemented this recommendation. The annual publication of tentatively scheduled advisory committee meetings will provide both advisory committee members and the public with the opportunity, in advance, to schedule attendance at FDA's upcoming advisory committee meetings. Because the schedule is tentative, amendments to this notice will not be published in the Federal Register. However, changes to the schedule will be posted on the FDA advisory committees' Internet site located at http://www.fda.gov/​AdvisoryCommittees/​default.htm. FDA will continue to publish a Federal Register notice 15 days in advance of each upcoming advisory committee meeting, to announce the meeting (21 CFR 14.20).

The following list announces FDA's tentatively scheduled advisory committee meetings for 2013. You may also obtain up-to-date information by calling the Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area) or on the FDA Internet Web site under our 2013 tentative scheduled meeting listing at http://www.fda.gov/​AdvisoryCommittees/​Calendar/​ucm153468.htm.

Table 1

Committee nameTentative date(s) of meeting(s)
OFFICE OF THE COMMISSIONER
Pediatric Advisory CommitteeMarch 14-15, September 19-20.
Risk Communication Advisory CommitteeFebruary 11-12, April 29-30, August 15-16, December 16-17.
Science Board to FDAFebruary 27, June 24, November 20.
CENTER FOR BIOLOGICS EVALUATION AND RESEARCH
Allergenic Products Advisory CommitteeNovember 5-6.
Blood Products Advisory CommitteeFebruary 12-13, April 8-9, August 1-2.
Cellular, Tissue and Gene Therapies Advisory CommitteeJanuary 15, April 17-18, June 27-28, October 24-25.
Transmissible Spongiform Encephalopathies Advisory CommitteeMarch 14-15.
Vaccines and Related Biological Products Advisory CommitteeFebruary 27, May 8-9 or July 17-18 (Backup date), September 18-19, November 13-14.
CENTER FOR DRUG EVALUATION AND RESEARCH
Anesthetic and Analgesic Drug Products Advisory CommitteeDate(s), if needed, to be determined.
Anti-Infective Drugs Advisory CommitteeDate(s), if needed, to be determined.
Antiviral Drugs Advisory CommitteeMay and October dates to be determined.
Arthritis Advisory CommitteeJuly or August and fall dates to be determined.
Cardiovascular and Renal Drugs Advisory CommitteeApril 17 and other date(s) to be determined.
Dermatologic and Ophthalmic Drugs Advisory CommitteeDate(s), if needed, to be determined.
Drug Safety and Risk Management Advisory CommitteeJanuary 24-25, March 5.
Endocrinologic and Metabolic Drugs Advisory CommitteeJanuary 10, July, and August dates to be determined.
Gastrointestinal Drugs Advisory CommitteeMarch 19 and other date(s) to be determined.
Medical Imaging Drugs Advisory CommitteeFebruary 14 and May date to be determined.
Nonprescription Drugs Advisory CommitteeDate(s), if needed, to be determined.
Oncologic Drugs Advisory CommitteeApril 5, May, June, July, September date(s) to be determined.
Pharmacy Compounding Drugs Advisory CommitteeDate(s), if needed, to be determined.
Peripheral and Central Nervous System Drugs Advisory CommitteeMay 22.
Advisory Committee for Pharmaceutical Science and Clinical PharmacologyDate(s), if needed, to be determined.
Psychopharmacologic Drugs Advisory CommitteeDate(s), if needed, to be determined.
Pulmonary-Allergy Drugs Advisory CommitteeJanuary 29-30, March 7.
Advisory Committee for Reproductive Health DrugsMarch 4-5, July 9.
Start Printed Page 105
CENTER FOR DEVICES AND RADIOLOGICAL HEALTH
Medical Devices Advisory Committee (Comprised of 18 Panels)
Anesthesiology and Respiratory Therapy Devices PanelDate(s), if needed, to be determined.
Circulatory System Devices PanelMay 17, May 24, June 27, September 27, November 22.
Clinical Chemistry and Clinical Toxicology Devices PanelApril 25.
Dental Products PanelDate(s), if needed, to be determined.
Ear, Nose, and Throat Devices PanelJuly 12.
Gastroenterology-Urology Devices PanelApril 24, May 16.
General and Plastic Surgery Devices PanelJune 13.
General Hospital and Personal Use Devices PanelJune 28, August 30.
Hematology and Pathology Devices PanelDate(s), if needed, to be determined.
Immunology Devices PanelDate(s), if needed, to be determined.
Medical Devices Dispute Resolution PanelDate(s), if needed, to be determined.
Microbiology Devices PanelJune 14.
Molecular and Clinical Genetics PanelSeptember 13.
Neurological Devices PanelFebruary 22.
Obstetrics and Gynecology Devices PanelSeptember 20.
Ophthalmic Devices PanelJune 14, August 23.
Orthopaedic and Rehabilitation Devices PanelApril 5, September 26.
Radiological Devices PanelSeptember 12.
Device Good Manufacturing Practice Advisory CommitteeApril 11.
National Mammography Quality Assurance Advisory CommitteeOctober 25.
Technical Electronic Product Radiation Safety Standards CommitteeDate(s), if needed, to be determined.
CENTER FOR FOOD SAFETY AND APPLIED NUTRITION
Food Advisory CommitteeJuly 15-16, August 29-30, September 23-24.
CENTER FOR TOBACCO PRODUCTS
Tobacco Products Scientific Advisory CommitteeFeb 11-12, April 30-May 1.
CENTER FOR VETERINARY MEDICINE
Veterinary Medicine Advisory CommitteeDate(s), if needed, to be determined.
NATIONAL CENTER FOR TOXICOLOGICAL RESEARCH (NCTR)
Science Advisory Board to NCTRDecember 10-11.
Start Signature

Dated: December 26, 2012.

Leslie Kux,

Assistant Commissioner for Policy.

End Signature End Supplemental Information

[FR Doc. 2012-31475 Filed 12-31-12; 8:45 am]

BILLING CODE 4160-01-P

Published Document